DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) and BioVie (NASDAQ:BIVI – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Volatility and Risk
DiaMedica Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for DiaMedica Therapeutics and BioVie, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DiaMedica Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| BioVie | 0 | 0 | 1 | 1 | 3.50 |
Earnings and Valuation
This table compares DiaMedica Therapeutics and BioVie”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DiaMedica Therapeutics | N/A | N/A | -$19.38 million | ($0.60) | -5.88 |
| BioVie | N/A | N/A | -$32.12 million | ($9.76) | -0.08 |
DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DiaMedica Therapeutics and BioVie’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DiaMedica Therapeutics | N/A | -43.67% | -40.81% |
| BioVie | N/A | -134.07% | -93.44% |
Institutional & Insider Ownership
10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 7.3% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 4.0% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
DiaMedica Therapeutics beats BioVie on 8 of the 12 factors compared between the two stocks.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About BioVie
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
